Abivax finalizes an oversubscribed $800 million ADS public offering

Abivax announced the pricing of its significantly oversubscribed public offering of US$800 million (€702 million) for its American Depositary Shares (ADS). The offering, initially planned at US$600 million, was increased to US$800 million, with a price of US$125.00 per ADS. This transaction is expected to extend the company's cash flow through the second quarter of 2029, supporting the potential commercialization of obefazimod and its continued clinical development.

The company hopes to generate gross proceeds of $800 million before the potential exercise of an over-allotment option. This option would allow the sale of up to 960,000 additional ADSs. Following this offering, shareholders are expected to experience a dilution of 8.0% to 9.2%, depending on whether or not the over-allotment option is exercised.